Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin

BMJ Open Diabetes Research and Care

Volumn 4, Issue 1, 2016, Pages

  Levin, Philip A ^a   Heinemann, Lutz ^b   Boss, Anders ^c   Rosenblit, Paul D ^d  

^a MODEL Clinical Research   (United States)

^b Profil Institut fur Stoffwechselforschung   (Germany)

^c SANOFI   (France)

^d Diabetes/Lipid Management and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FUMARYL DIKETOPIPERAZINE; INSULIN; PIPERAZINEDIONE; TECHNOSPHERE INHALED INSULIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; FEEDING BEHAVIOR; FEMALE; FUMARYL DIKETOPIPERAZINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHARMACODYNAMIC PARAMETERS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION;

EID: 85000770159     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2016-000228     Document Type: Article

References (14)

1. Potocka E, Cassidy JP, Haworth P, et al. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol 2010;4:1164-73.
2. Cassidy JP, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration. Pharm Res 2011;28:2157-64.
3. Novo Nordisk. Insulin aspart prescribing information. 2015. http://www.novo-pi.com/novolog.pdf (accessed 5 Aug 2015).
4. Eli Lilly and Company. Insulin lispro prescribing information. 2015. http://pi.lilly.com/us/humalog-pen-pi.pdf (accessed 8 Jan 2016).
5. Herbst KL, Hirsch IB. Insulin strategies for primary care providers. Clin Diabetes 2002;20:11-17.
6. Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab 2012;14:163-73.
7. Rave K, Potocka E, Heinemann L, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab 2009;11:715-20.
8. Bode BW, McGill JB, Lorber DL, et al. Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care 2015;38:2266-73.
9. Sanofi. Afrezza prescribing information. 2015. http://products.sanofi.us/afrezza/afrezza.pdf (accessed 19 Aug 2015).
10. Fendrick AM, Monto AS, Nightengale B, et al. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003;163:487-94.
11. McElduff A, Mather LE, Kam PC, et al. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System. Br J Clin Pharmacol 2005;59:546-51.
12. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-6.
13. Gern JE, Stone CK, Nakano M, et al. Effect of upper respiratory tract infection on AIR inhaled insulin pharmacokinetics and glucodynamics in healthy subjects. Clin Pharmacol Ther 2008;83:307-11.
14. Camus P. Effect of intercurrent respiratory tract infections on inhaled human insulin (Exubera) therapy: a retrospective pooled analysis of controlled phase 2 and 3 trials. Diabetologia 2006;49(Suppl 1): 616-7.